Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,167,624
  • Shares Outstanding, K 1,504,216
  • Annual Sales, $ 28,216 M
  • Annual Income, $ 5,309 M
  • 36-Month Beta 1.46
  • Price/Sales 4.37
  • Price/Cash Flow 13.24
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.91
  • Number of Estimates 7
  • High Estimate 2.01
  • Low Estimate 1.88
  • Prior Year 1.48
  • Growth Rate Est. (year over year) +29.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.41 +8.60%
on 12/20/18
92.99 -3.75%
on 12/31/18
+5.92 (+7.08%)
since 12/18/18
3-Month
77.50 +15.48%
on 11/01/18
94.98 -5.77%
on 12/04/18
-0.40 (-0.44%)
since 10/18/18
52-Week
77.50 +15.48%
on 11/01/18
125.86 -28.89%
on 01/26/18
-14.31 (-13.78%)
since 01/18/18

Most Recent Stories

More News
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced an update on the Phase 3 RESOLVE trial (PCYC-1137) of ibrutinib (IMBRUVICA®) in combination with chemotherapy agents...

ABBV : 89.50 (+2.64%)
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABBV : 89.50 (+2.64%)
Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ABBV : 89.50 (+2.64%)
Are you a Tortoise or a Hare Investor?

Some love the latest IPO and others invest in the tried and true. All investors should know their investing style

FIVE : 122.68 (+1.91%)
CROX : 29.39 (-4.24%)
VOOG : 143.46 (+1.16%)
ABBV : 89.50 (+2.64%)
JILL : 6.34 (+5.49%)
Pacira's Study on Exparel Label Expansion Meets Endpoints

Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.

MRK : 75.87 (+0.36%)
LLY : 116.59 (-2.16%)
ABBV : 89.50 (+2.64%)
PCRX : 40.04 (+3.38%)
Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

OXY : 67.03 (+1.82%)
T : 30.96 (+1.04%)
VZ : 57.09 (+0.46%)
ABBV : 89.50 (+2.64%)
GILD : 69.18 (+0.77%)
Banks Keep Stocks Moving Higher

Banks Keep Stocks Moving Higher

GOOGL : 1,107.30 (+0.74%)
AMTD : 55.37 (+1.86%)
CVX : 114.37 (+2.15%)
JNJ : 130.69 (+1.24%)
COUP : 76.66 (+4.13%)
SQQQ : 13.32 (-2.84%)
ALRM : 60.38 (+4.18%)
NICE : 106.11 (+0.53%)
ADM : 44.26 (+1.96%)
ABBV : 89.50 (+2.64%)
HDV : 87.29 (+1.39%)
SNX : 91.60 (+0.90%)
Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

KTOV : 1.33 (-7.64%)
ATNX : 12.05 (+1.35%)
LLY : 116.59 (-2.16%)
ABBV : 89.50 (+2.64%)
Will Dividend Stocks be the Hot Stocks of 2019?

With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.

OXY : 67.03 (+1.82%)
T : 30.96 (+1.04%)
VZ : 57.09 (+0.46%)
ABBV : 89.50 (+2.64%)
GILD : 69.18 (+0.77%)
5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.

NVO : 48.05 (+0.84%)
MRK : 75.87 (+0.36%)
LLY : 116.59 (-2.16%)
ABBV : 89.50 (+2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 91.61
1st Resistance Point 90.55
Last Price 89.50
1st Support Level 87.68
2nd Support Level 85.87

See More

52-Week High 125.86
Fibonacci 61.8% 107.39
Fibonacci 50% 101.68
Fibonacci 38.2% 95.97
Last Price 89.50
52-Week Low 77.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar